The solution was launched at the India Innovation Summit: Pioneering Solutions to End TB today, as a next-generation solution (NGS) empowering labs and hospitals with genomic sequencing capabilities to enhance TB treatment outcomes
March 19th, 2025: In a move to bolster India’s fight against tuberculosis (TB), HaystackAnalytics has introduced ‘TB One,’ a Make-in-India solution designed to enhance TB diagnosis by enabling Next-Generation Sequencing (NGS) at any diagnostic lab or hospital. This all-in-one offering includes a pre-sequencing kit for Whole Genome Sequencing (WGS), access to ‘Omega TB’—HaystackAnalytics’ patented clinical reporting software—and on-demand access to 2GB of sequencing data. The Omega TB software delivers a comprehensive clinical report covering resistance to 18 anti-TB drugs, along with mixed infections, non-tuberculous mycobacteria (NTM), and heteroresistance—all within a single, standardized report. By equipping healthcare providers with precise, data-driven insights, ‘TB One’ aims to improve TB management and strengthen India’s fight against the disease.
The Solution has been unvieled by Dr Anirvan Chatterjee, Co-founder & CEO, HaystackAnalytics & Dr Rajendra Prasad at Indian Council of Medical Research’s (ICMR) India Innovation Summit: Pioneering Solutions to End TB on March 19, 2025. With this solution genomics-based TB testing would become more accessible and scalable by enabling existing laboratories to upgrade to NGS testing for TB without significant infrastructure changes. This solution aligns seamlessly with HaystackAnalytics’ mission to make genomics accessible, applicable, and affordable, addressing a critical need to transform molecular diagnostic laboratories into advanced genomic facilities.
India has made significant strides in TB control, achieving a 17.7% decline in TB incidence from 2015 to 2023, surpassing the global average reduction of 8.3%. However, challenges persist, with an estimated 27.8 lakh TB cases and 3.2 lakh TB-related deaths reported in 2023. Notably, India contributes to 26% of the global TB burden, underscoring the urgency for innovative diagnostic solutions. Additionally, drug-resistant TB remains a major obstacle to eliminating the disease. ‘TB One’ solution is designed to address this challenge by providing a comprehensive solution for drug resistance profiling, making advanced genomic testing more accessible to healthcare providers.
Emphasizing on the transformative potential of ‘TB One’ solution, Dr. Anirvan Chatterjee, Co-founder and CEO of HaystackAnalytics, said, “We are empowering existing molecular labs to perform high-precision genomic testing without requiring expensive infrastructure modifications. This cost-effective and scalable approach ensures greater accessibility to advanced TB diagnostics across India. Each TB One kit contains reagents to process 16 samples and requires prior extraction of TB DNA. It seamlessly integrates into existing molecular workflows, facilitating efficient TB genomic sequencing.”
Dr. Rajendra Prasad, a nationally acclaimed pulmonologist with over 51 years of experience in TB care and research, said, “Drug-resistant TB remains one of our toughest challenges, and faster, more precise diagnostics are the need of the hour. ‘TB One’ Solution can be a game-changer, bringing advanced genomic testing to everyday labs without major upgrades. By enabling comprehensive drug resistance profiling in a single test, it has the potential to help in TB care and save countless lives. This is a crucial step toward the journey of TB Mukt Bharat.”
‘TB One’ Solution is a pre-sequencing kit that enables the preparation of a ready-to-sequence library from TB DNA. It simplifies the complex process of genomic testing, allowing laboratories and hospitals to integrate groundbreaking technology into their existing workflows. This advancement enables laboratories to conduct comprehensive drug resistance profiling with unprecedented precision and efficiency.
About HaystackAnalytics:
Based out of IIT Bombay, HaystackAnalytics is a HealthTech company creating clinical genomics products, which enable diagnostic labs and hospitals to offer accurate and personalized diagnostics. Supported by India’s most respected science agencies (Dept. of Science & Technology, BIRAC, Dept. of Bio-Tech), HaystackAnalytics has created and launched a portfolio of products to offer genomics in infectious and chronic diseases. The company has been honored with a few innovative healthcare startup awards, including CAHO Tech- PitchFest for healthcare startups, HealthTech startup of the year by The Entrepreneur magazine, Aegis Graham Bell Award, and recently HaystackAnalytics’s platform for rapid identification of drug resistance in TB patients was launched by our Honorable Prime Minister Narendra Modi at BIRAC’s Biotech Startup Expo 2022 in New Delhi. For more information, visit https://haystackanalytics.in/